CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment

Keyphrases

• Anti-tumor Response 8%
• Anticancer Immune Response 8%
• Anticancer Immunity 100%
• Antigen-specific T Cell Response 8%
• Antitumor Efficacy 8%
• C57BL 8%
• Cancer Patients 8%
• Cancer Types 8%
• CCL22 100%
• CCR4 8%
• CD8+ Cells 8%
• CD8+ Tregs 8%
• Cellular Composition 8%
• Chemokines 8%
• Derived Peptide 8%
• Immune Cells 8%
• Immune Milieu 8%
• Immunotherapeutics 8%
• In Cancer 8%
• Infiltration 8%
• Interferon-α (IFN-α) 8%
• M1 Macrophages 8%
• M2 Macrophages 8%
• Macrophages 8%
• Mouse Model 8%
• Multicolor Flow Cytometry 8%
• Peptide Vaccine 100%
• Prolonged Survival 8%
• Regulatory T Cells 8%
• Specific T Cells 8%
• Syngeneic Mouse Model 8%
• Targeted Immunotherapy 8%
• Tumor Cells 8%
• Tumor Growth 8%
• Tumor Microenvironment 100%
• Vaccination 16%

Immunology and Microbiology

• C57BL 6 Mouse 8%
• CCL22 100%
• CCR4 8%
• CD8 8%
• CD8+ Cell 8%
• Chemokine 8%
• Immune Response 8%
• Immunocompetent Cell 8%
• Immunosuppressive Drug 8%
• Immunotherapy 8%
• Interferon Type I 8%
• M2 Macrophages 8%
• Macrophage 16%
• Mouse 8%
• Mouse Model 8%
• Peptide Vaccine 100%
• Regulatory T Cell 16%
• Secretion (Process) 8%
• Syngenic 8%
• T Cell 16%
• Tumor Cell 8%
• Tumor Immunity 100%
• Vaccination Policy 16%